What is the core difference between Zepbound and Wegovy?
Zepbound and Wegovy are both once-weekly injectable medicines approved by the FDA for chronic weight management, and both work through the incretin system. The headline difference is how many receptors each one activates. Wegovy, whose molecule is semaglutide, is a single agonist: it targets the GLP-1 receptor. Zepbound, whose molecule is tirzepatide, is a dual agonist — it targets both the GIP receptor and the GLP-1 receptor.
That extra receptor arm is the mechanistic reason the two are often discussed together but expected to behave differently. Adding GIP-receptor activity on top of GLP-1 is the rationale for why tirzepatide has tended to produce larger weight-loss figures, and as of 2026 there is direct head-to-head evidence — discussed below — comparing the two in adults with obesity.
It is worth stating clearly up front that neither drug is investigational. Both are FDA-approved medicines that a clinician can prescribe for chronic weight management, each with its own label, dosing schedule, and additional approved indication. The choice between them is a clinical one, not a question of whether one is "real" and the other experimental.
A useful way to frame the rest of this comparison is that the two drugs are alike in shape but different in specifics. Both are once-weekly subcutaneous injections, both are titrated slowly to manage gastrointestinal side effects, and both act on the GLP-1 receptor that drives appetite and satiety signaling. Where they part ways is the second receptor Zepbound engages, the magnitude of weight loss they produced when measured against each other, and the distinct extra conditions each is approved to treat — and those are the threads the sections below pull on one at a time.
Which produced more weight loss head-to-head?
Unlike many drug comparisons that rely on stitching together separate trials, Zepbound and Wegovy have been compared directly. SURMOUNT-5 was a phase 3b, open-label head-to-head trial in 751 adults with obesity who did not have diabetes, run over 72 weeks, comparing tirzepatide against semaglutide. This makes it the centerpiece of any honest Zepbound-versus-Wegovy discussion, because both drugs were measured in the same population, over the same duration, at the same time.
In that trial, tirzepatide produced a mean weight reduction of −20.2%, while semaglutide produced −13.7%. Tirzepatide also produced a larger reduction in waist circumference, −18.4 cm versus −13.0 cm. Because this is a single trial with both arms run side by side, the difference is a genuine head-to-head comparison rather than an indirect inference from two unrelated studies.
That said, SURMOUNT-5 was open-label, meaning participants and investigators knew which drug was being given, and it enrolled adults with obesity without diabetes — so its results describe that specific population. The averages are also just averages: individual response varies widely, which is why the trial also reported how many people crossed specific weight-loss thresholds, covered in the next section.
It is also worth putting the semaglutide arm in context. The −13.7% figure in SURMOUNT-5 sits in the same range semaglutide produced in its own pivotal obesity trial, STEP 1, where 2.4 mg once weekly reduced body weight by a mean of −14.9% over 68 weeks versus −2.4% on placebo. In other words, both arms of the head-to-head trial performed in line with what each drug had shown separately — the comparison did not make either drug look unusually weak or strong, which is part of why the side-by-side result is credible.
How many people hit ≥15%, ≥20%, or ≥25% weight loss?
Average weight loss hides how many people actually reach meaningful milestones, so SURMOUNT-5 reported responder rates — the share of participants reaching each threshold — for both drugs. The pattern is consistent: at every threshold, a larger proportion of the tirzepatide (Zepbound) group hit the target than the semaglutide (Wegovy) group.
At least 10% weight loss was reached by 81.6% of the tirzepatide group versus 60.5% of the semaglutide group. At least 15% was reached by 64.6% versus 40.1%. At least 20% was reached by 48.4% versus 27.3%. And at the most demanding threshold, at least 25% weight loss, 31.6% of the tirzepatide group got there versus 16.1% of the semaglutide group.
These responder figures are arguably more useful than the headline averages, because weight loss in the 15–25% range is where many clinically important outcomes tend to cluster. The takeaway from SURMOUNT-5 is not that one drug works and the other does not — both moved a large share of people past meaningful thresholds — but that a higher proportion reached the deeper milestones on tirzepatide.
What can each drug do beyond weight loss?
Beyond chronic weight management, Zepbound and Wegovy diverge in their additional approved indications, and this is often the deciding factor for an individual patient. They are not interchangeable on this point: each carries an approval the other does not.
Wegovy (semaglutide) is additionally approved to reduce cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight. That approval is grounded in the SELECT trial, which studied semaglutide in people with obesity and established cardiovascular disease but without diabetes. In SELECT, major adverse cardiovascular events (MACE) occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, a hazard ratio of 0.80 (95% CI 0.72–0.90) — a meaningful reduction in cardiovascular events.
Zepbound (tirzepatide), in contrast, carries an additional approval the other lacks: in December 2024 it was approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. So a patient whose primary concern is cardiovascular risk and one whose primary concern is sleep apnea may be steered toward different drugs — not because of weight loss alone, but because of these distinct second indications.
How are Zepbound and Wegovy dosed?
Both are once-weekly subcutaneous injections that are deliberately titrated upward over weeks. The slow start is not a weakness of either drug — it is how incretin medicines limit early gastrointestinal side effects while the body adapts.
Wegovy (semaglutide) follows a five-step titration: 0.25 mg, then 0.5 mg, then 1 mg, then 1.7 mg, and finally the 2.4 mg maintenance dose, escalating roughly every four weeks. The 2.4 mg dose is the target maintenance dose for weight management.
Zepbound (tirzepatide) starts at 2.5 mg once weekly for four weeks — an introductory dose meant to limit nausea, not to drive weight loss — then steps up to 5 mg, and can be increased in 2.5 mg increments no sooner than every four weeks. The approved maintenance doses are 5, 10, or 15 mg once weekly, and the maximum is 15 mg weekly. The practical point is that both have a defined, label-driven schedule a clinician can follow; the actual dose and pace should always be set by the prescriber.
How do the side effects and tolerability compare?
The side-effect profiles look broadly similar because both drugs act through the GLP-1 receptor. In both, the dominant adverse events are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and in both they are dose-dependent and tend to ease as the body adapts to gradual dose escalation. This is the main reason both follow a slow, stepwise titration.
SURMOUNT-5, because it ran both drugs side by side, also lets us compare how often people stopped treatment because of side effects. Discontinuation due to adverse events occurred in 6.1% of the tirzepatide (Zepbound) group versus 8.0% of the semaglutide (Wegovy) group — a slightly lower rate on tirzepatide in that trial.
That difference is modest and comes from a single open-label study, so it should not be over-read as a definitive verdict on tolerability. Individual experience varies considerably, and the same person can tolerate one incretin drug better than another. How side effects play out for a given patient — and how to manage them — is exactly the kind of judgment a prescribing clinician is there to make.
Which one is right for you?
For most people the comparison is not "which drug is better" in the abstract but "which drug fits my situation." Both are FDA-approved, both produce substantial weight loss, and both are dosed once weekly with a similar style of side-effect management. SURMOUNT-5 showed greater average weight loss and higher responder rates on Zepbound (tirzepatide), with a slightly lower rate of discontinuation due to side effects in that single trial.
But the additional indications often matter just as much. If you have established cardiovascular disease alongside obesity or overweight, Wegovy (semaglutide) carries an approval to reduce cardiovascular risk that Zepbound does not. If you have moderate-to-severe obstructive sleep apnea with obesity, Zepbound carries an approval for that indication that Wegovy does not. Other factors — your history, your tolerance, insurance coverage, and what your clinician judges safest — all feed into the decision.
None of this is medical advice or an endorsement of either drug. The right choice belongs with a licensed clinician who can weigh your goals, your medical history, and your risk factors, and who can manage titration and monitoring over time.
Tracking either on PeptidePanel
Whichever medicine a clinician prescribes, the day-to-day work is the same: log doses, watch the markers that matter (weight trend, waist circumference, blood pressure, lipids, and any labs your clinician orders), and catch side effects early. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your measurements over time, and reminds you when a dose is due.
PeptidePanel does not sell, source, or supply any medication. It is a monitoring tool for protocols that a qualified prescriber has put you on — Zepbound, Wegovy, or anything else.